Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

Michel Attal; Valérie Lauwers‐Cancès; Cyrille Hulin; Xavier Leleu; Denis Caillot; Martine Escoffre; Bertrand Arnulf; Margaret Macro; Karim Belhadj; Laurent Garderet; Murielle Roussel; Catherine Payen; Claire Mathiot; Jean Paul Fermand; Nathalie Meuleman; Sandrine Rollet; Michelle E. Maglio; Andrea A. Zeytoonjian; Edie Weller; Nikhil C. Munshi; Kenneth C. Anderson; Paul G. Richardson; Thierry Façon; Hervé Avet‐Loiseau; Jean‐Luc Harousseau; Philippe Moreau

doi:10.1056/nejmoa1611750

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Among adults with multiple myeloma, RVD therapy plus transplantation was associated with significantly longer progression-free survival than RVD therapy alone, but overall survival did not differ significantly between the two approaches. (Supported by Celgene and others; IFM 2009 Study ClinicalTrials.gov number, NCT01191060 .).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Attal et al. (2017) studied this question.

synapsesocial.com/papers/69dbc19bc9a120f055a3c6ee https://doi.org/10.1056/nejmoa1611750

View Full Paper

Ask AI

Bookmark

Share

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

Ask about this paper

Abstract

Discussion

Cite This Study

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading